araag2/HINT huggingface dataset:
Clinical trial NCT02113267 (phase 2, status: terminated)
Conditions: eosinophilic esophagitis
ICD codes: K20.0
Drugs: mometasone furoate, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    combination slow recruitment, short shelf life for placebo and insufficient funding for further
    drug production (probably anyway sufficient number included).
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age over 18 years

          -  Newly diagnosed cases with diagnostic criteria for EoE (ie at least 15 eosinophils per
             high power field (Magnification 10 times 40 = x400) in any field of view in any
             esophageal biopsy and concurrent symptoms of esophageal dysfunction mainly dysphagia.

          -  Women of childbearing age may participate provided that the pregnancy is not planned ,
             and that contraceptive use during therapy. The investigator will arrange a free
             pregnancy test must be performed within 1 week before treatment and be negative.

          -  Participation requires oral and written informed and signed consent form (see patient
             information and consent forms).

        Exclusion Criteria:

          -  Local infection of the pharynx or esophagus , such as fungal, bacterial or viral
             infection

          -  Active or latent tuberculosis in respiratory tract

          -  Recent history of major trauma or major surgery

          -  Recent significant infection or other physical stress

          -  Signs or suspicion of dehydration

          -  History of injury, illness or surgery in the adrenals or pituitary

          -  Pharynx or esophagussurgery or other trauma in the esophagus (incl. foreign body with
             a sharp object ) where healing has not taken place. (in case of doubt to be assessed
             by esophago - gastroscopy.

          -  Planned elective surgery during treatment

          -  Pregnancy, ongoing or planned

          -  Women of childbearing potential not using preventives during the study period

          -  Glaucoma

          -  Hypersensitivity to any component in the treatments

          -  Systemic or local steroid treatment last 4 months

          -  Contraindication to steroid therapy ( immune deficiency or suppression , stomach
             ulcers, diabetes)

          -  Medications that affect oesophageal motility (cisapride, erythromycin ) during the
             treatment period .

          -  PPIs during or up to 2 weeks before the treatment period

          -  Other cause of dysphagia (cancer, connective tissue disease , neurological disease )

          -  Volunteer who can not consent to the study or complete a questionnaire
Clinical trial NCT02113826 (phase 2, status: terminated)
Conditions: metastatic alveolar soft part sarcoma
ICD codes: J84.09, J84.01, J84.02, M26.70, M26.71, M26.72, M26.73
Drugs: pazopanib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    low accrual rate
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion
             at stage IV or at relapse

          -  Age ≥ 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Measurable lesion defined by RECIST v1.1

          -  Chemo-naïve or prior chemotherapies

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior malignancies

          -  Active CNS disease

          -  High-risk for gastrointestinal bleeding

          -  Significant cardiovascular disease

          -  Uncontrolled hypertension

          -  Bleeding diathesis
Clinical trial NCT02114658 (phase 2, status: completed)
Conditions: thyroid carcinoma
ICD codes: D09.3
Drugs: sorafenib (nexavar,bay43-9006)
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese patients with ATC (Anaplastic thyroid carcinoma) or locally advanced or
             metastatic MTC (medullary thyroid carcinoma)

          -  Not a candidate for surgery or radiotherapy with curative intent

          -  Histologically or cytologically confirmed ATC or MTC

          -  Measurable or non-measurable disease (but clinically evaluable) according to RECIST
             1.1.

          -  Age >= 18 years

          -  Adequate bone marrow, liver and renal function to be conducted within 14 days prior to
             treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma

          -  Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies
             (licensed or investigational) that target VEGF or VEGF (vascular endothelial growth
             factor) receptors or other targeted agents

          -  Prior chemotherapy for thyroid cancer (only one regimen is allowed)

          -  Major surgery, open biopsy, or significant traumatic injury within 30 days prior to
             enrollment in the study.

          -  Subjects with tracheal, bronchial or esophageal infiltration with significant risk of
             bleeding but without having received local treatment prior to enrollment in the study
Clinical trial NCT02115464 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: metformin plus chemo-radiotherapy
SMILES: CN(C)C(=N)NC(N)=N
Reason stopped: 
    the accrual rate was not high enough to reach the target sample size.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age >/=18 to </= 80 years of age.

          2. Unresected and pathologically (histologic) proven Stage 3a or Stage 3b NSCLC of
             adenocarcinoma, squamous cell, large cell or mixed histology, diagnosed within three
             months of study randomization.

          3. Non-metastatic disease staged by: CT-chest and upper abdomen, brain MRI or
             contrast-enhanced CT within 12 weeks and physical examination and whole body
             FDG-PET/CT scan within 8 weeks prior to study randomization.

        Exclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status >2.

          2. More than 10% weight loss in the past 3 months.

          3. Diabetic patient or anyone currently taking Metformin, insulin or other
             anti-hyperglycemic therapy.

          4. Pulmonary Function Test (PFTs) (within the last 12 weeks) with Forced Expiratory
             Volume (FEV)1 < 1.2 litres per second or less than 50% of predicted.

          5. Complete Blood Count (CBC) and biochemical renal and liver function profiles that do
             not permit chemotherapy treatment (as per institutional standard of care).

          6. Fasting blood sugar levels of >/= 7.0 mmol per litre (within the last 12 weeks).

          7. Prior systemic chemotherapy for lung cancer.

          8. Prior radiotherapy that would overlap with the planned treatment area.

          9. Prior invasive malignancy within the past 3 years (except non-melanomatous skin cancer
             non-invasive carcinoma in-situ of the breast, oral cavity or cervix).

         10. Known Acquired Immune Deficiency Syndrome (AIDS).

         11. Patients with increased risk for lactic acidosis:

               -  severe congestive heart failure (NYHA: class III or IV),

               -  history of metabolic acidosis,

               -  alcoholic intake of > 3 drinks daily,

               -  severe liver disease,

               -  renal failure

         12. Known hypersensitivity or allergy to Metformin.

         13. Known pregnancy or lactating female patient.

         14. Geographic inaccessibility for follow-up.

         15. Inability to provide informed consent.
Clinical trial NCT02116361 (phase 2, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: normal saline
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate to severe major depressive disorder

        Exclusion Criteria:

          -  Prior treatment with botulinum toxin of any serotype for any reason

          -  Use of antidepressant medication for depression within 2 weeks of study

          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
Clinical trial NCT02117258 (phase 2, status: completed)
Conditions: metastatic pancreatic adenocarcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: z-360, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  1. Subjects with histological or cytological evidence of metastatic Pancreatic
             Adenocarcinoma, Measurable disease or non-measurable disease by Response Evaluation
             Criteria in Solid Tumors (RECIST) version criteria

          -  2. Subjects with a life expectancy of at least 12 weeks,

          -  3. Subjects with an Eastern cooperative oncology group performance status (ECOG PS) of
             0, 1 or 2,

          -  4. Subjects with the following adequate organ functions:

               -  White blood cell count ≥3,000/μL (or absolute neutrophil count ≥1,500/μL) and ≤
                  12,000/μL ,

               -  Platelet count ≥100.0 × 10^9/L,

               -  Hemoglobin ≥9.0 g/dL,

               -  Serum creatinine ≤1.5 × the upper limit normal (ULN),

               -  Total bilirubin ≤2.0 × ULN,

               -  Serum aspartate transaminase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver
                  metastases), and

               -  Serum alanine aminotransferase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver
                  metastases).

        Exclusion Criteria:

          -  Subjects received the following previous therapies for Pancreatic Adenocarcinoma:

               -  Surgery within the 4 weeks prior to randomization,

               -  Radiation and chemoradiation within the 12 weeks prior to randomization,

               -  Radiation for pain relief within the 4 weeks prior to randomization,

               -  Gemcitabine used as a neoadjuvant or an adjuvant on surgery within the 24 weeks
                  prior to randomization,

               -  Chemotherapy except GEM used as an adjuvant on surgery within the 4 weeks prior
                  to randomization,

               -  Gemcitabine ≥600 mg/m^2 as sensitizer for chemoradiation,

               -  Gemcitabine <600 mg/m^2 as sensitizer for chemoradiation within the 12 weeks
                  prior to randomization,

               -  Gemcitabine used for systemic chemotherapy, or

               -  Systemic chemotherapies except GEM within the 4 weeks prior to randomization.
Clinical trial NCT02119650 (phase 2, status: terminated)
Conditions: nsclc (non-small cell lung carcinoma)
ICD codes: D02.20, D02.21, D02.22
Drugs: ruxolitinib, placebo, pemetrexed, cisplatin
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    the study was terminated as other related studies of ruxolitinib did not provide sufficient
    efficacy to warrant continuation.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage
             IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery,
             or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).

          -  Radiographically measurable or evaluable disease.

          -  Life expectancy of at least 12 weeks.

          -  Tumor without activating driver mutations for which there is available therapy (eg,
             tumor without mutations in epidermal growth factor receptor or anaplastic lymphoma).

          -  An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:

               -  Criteria:

                    -  C-reactive protein >10 mg/L AND albumin ≥35 g/L; Score = 1

                    -  C-reactive protein >10 mg L AND albumin <35 g/L; Score = 2

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          -  Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified
             laboratory parameters at the screening visit.

        Exclusion Criteria:

          -  Squamous or mixed histology (eg, adenosquamous) NSCLC

          -  Previous systemic therapy for advanced or metastatic disease.

          -  Known active central nervous system (CNS) metastases.

          -  Current or previous other malignancy within 2 years of study entry, except cured basal
             or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial
             neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy
             without sponsor approval.

          -  Current uncontrolled cardiac disease such as angina or myocardial infarction,
             congestive heart failure including New York Heart Association functional
             classification of 3, or arrhythmia requiring treatment.

          -  Uncontrolled concomitant medical conditions, including, but not limited to, renal,
             hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral,
             or psychiatric diseases.
Clinical trial NCT02119676 (phase 2, status: terminated)
Conditions: crc (colorectal cancer)
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ruxolitinib, regorafenib, placebo
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    substudy 1 was terminated for futility at interim analysis and substudy 2 was terminated per
    sponsor decision.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that
             is metastatic.

          -  Previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan- based
             chemotherapy, an anti-VEGF therapy (if no contraindication) and if KRAS wild type and
             no contraindication, an anti-EGFR therapy.

          -  Radiographically measurable or evaluable disease (per RECIST v1.1)

          -  Life expectancy of ≥ 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Three or more weeks have elapsed from the completion of previous treatment regimen and
             subjects must have recovered or be at a new stable baseline from any related
             toxicities.

          -  Prior radiotherapy to disease sites is allowed with certain protocol-defined
             restrictions.

        Exclusion Criteria:

          -  Prior treatment with regorafenib.

          -  Presence of active gastrointestinal disease or other condition that will interfere
             significantly with the absorption of drugs.

          -  Active peptic ulcer disease, inflammatory bowel disease (eg, ulcerative colitis,
             Crohn's disease), diverticulitis, or other gastrointestinal conditions with increased
             risk of perforation or gastrointestinal bleeding.

          -  Recent history (≤ 3 months) or ongoing partial or complete bowel obstruction unless
             due to disease under study and corrected with surgery.

          -  Blood pressure ≥ 140/90 mmHg.

          -  Active bleeding diathesis or history of any major bleeding (eg, requiring transfusion
             of red blood cells (RBCs), central nervous system (CNS) bleeding, or significant
             hemoptysis within 6 months of enrollment. Subjects with bleeding secondary to
             underlying disease (including gastrointestinal (GI) perforation or fistula) that has
             been corrected by surgery or alternative procedure may be included.

          -  Clinically significant cardiac disease including unstable angina, acute myocardial
             infarction within 6 months from Day 1 of study drug administration, New York Heart
             Association Class II, III, or IV congestive heart failure, and arrhythmia requiring
             therapy.
Clinical trial NCT02119819 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2944876, exenatide extended-release, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women with diabetes mellitus Type 2

          -  Have screening HbA1c ≥7.0% and ≤10.5% either on diet and exercise alone or on a stable
             dose of metformin (≥1000 mg/day) for 3 months prior to screening

          -  Have body mass index (BMI) ≥23 and ≤45 kilograms per meter squared at screening

        Exclusion Criteria:

          -  Women of child bearing potential

          -  Participants who have used thiazolidinediones within 3 months prior to screening, or
             any other drugs for treatment of hyperglycemia (except metformin) within the prior 2
             months

          -  Participants who have used insulin for diabetic control for more than 6 consecutive
             days within the prior year

          -  Participants with impaired renal function (serum creatinine >124 micromole per liter
             (µmol/L) [1.4 milligrams per deciliter (mg/dL)] in women, >133 µmol/L [1.5 mg/dL] in
             men)
Clinical trial NCT02120300 (phase 2, status: completed)
Conditions: chronic hcv infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: ldv/sof, sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Hemophilia A, B or C, or Von Willebrand's disease

          -  Chronic genotype 1, 2, 3 or 4 HCV infection

          -  HCV RNA ≥ 1000 IU/mL at screening

          -  Use of protocol specified method(s) of contraception if female of childbearing
             potential or sexually active male

          -  Screening laboratory values within defined thresholds

          -  For HIV-1/HCV co-infected individuals:

               -  Suppressed HIV-1 RNA on an antiretroviral (ARV) regimen for at least 6 months
                  prior to screening

               -  Stable protocol-approved ARV regimen for > 8 weeks prior to screening

               -  CD4 T-cell count > 200 cells/mm^3 at screening

        Exclusion Criteria:

          -  Clinically-significant illness (other than HCV, inherited bleeding disorder or HIV-1)
             or any other major medical disorder that may interfere with subject treatment,
             assessment or compliance with the protocol

          -  Current or prior history of any of the following:

               -  Hepatic decompensation

               -  Chronic liver disease of a non-HCV etiology

               -  Hepatocellular carcinoma (HCC)

               -  Infection with hepatitis B virus (HBV)

          -  Pregnant or nursing female

          -  Prior treatment with inhibitors of nonstructural protein 5A (NS5A) or the NS5B
             polymerase

          -  Chronic use of systemically administered immunosuppressive agents

          -  For HIV-1/HCV co-infected individuals:

               -  Opportunistic infection within 6 months prior to screening

               -  Active, serious infection (other than HIV-1 or HCV) requiring parental
                  antibiotics, antivirals or antifungals within 30 days prior to baseline
Clinical trial NCT02121301 (phase 2, status: completed)
Conditions: keratoconjunctivitis sicca
ICD codes: H16.223, H16.221, H16.222, H16.229
Drugs: low dose 0.155µg/ml skq1 ophthalmic solution, high dose 1.55µg/ml skq1 ophthalmic solution, placebo (vehicle) opthalmic solution
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be male or female of any race, at least 18 years of age

          -  Have provided written informed consent

          -  Have a reported history of dry eye syndrome

          -  Have a history of use or desire to use eye drops for dry eye

        Exclusion Criteria:

          -  Have any clinically significant eye findings that require therapeutic treatment or may
             interfere with study parameters

          -  Have previously had LASIK surgery within the last 12 months

          -  Have used Restasis® within 30 days of Visit 1

          -  Be a woman who is pregnant, nursing or planning a pregnancy

          -  Be unwilling to submit a urine pregnancy test if of childbearing potential

          -  Have a known allergy and/or sensitivity to the test article or its components,
             including the preservative benzalkonium chloride

          -  Be currently enrolled in an investigational drug or device study or have used an
             investigational drug or device within 30 days of Visit 1

          -  Have a condition or be in a situation which the investigator feels may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with the subject's participation in the study
Clinical trial NCT02127866 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: chf 5259 plus foster 100/6 µg, foster 100/6 µg
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients aged >=18 years

          -  Uncontrolled asthma on medium doses of ICS+LABA with ACQ >=1.5

          -  Pre-bronchodilator FEV1 ≥40% and <80% of their predicted normal value

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Diagnosis of COPD

          -  Patients treated for asthma exacerbations in the 4 weeks prior to study entry

          -  Patients who are in therapy for gastroesophageal reflux disease

          -  Patients who have a clinically significant cardiovascular condition
Clinical trial NCT02127996 (phase 2, status: active, not recruiting)
Conditions: angina pectoris, myocardial infarction, reperfusion injury, coronary heart disease
ICD codes: I20.9, I20.1, I20.8, I25.10, I25.810, I25.110, I25.119, I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8, I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: glp-1, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Undergoing elective PCI

          -  Age over 18

          -  Able to give informed consent

        Exclusion criteria:

          -  Severe co-morbidity (expected life expectancy < 6 months)

          -  Nicorandil, glibenclamide, sitagliptin, vildagliptin, saxagliptin, linagliptin,
             liraglutide, exenatide and insulin use

          -  Women of child bearing age

          -  Breast-feeding women

          -  Myocardial infarction within the previous 3 months

          -  Baseline elevation of Troponin I before PCI

          -  Chronic Renal Impairment (serum creatinine > 160 μmol/l)